Peanut Allergy | ESM Magazine

European Commission Approves Aimmune's Peanut Allergy Treatment

Nestlé has announced that the European Commission has approved the use of Aimmune's peanut allergy treatment Palforzia in the EU. The a...

Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia. Aimmu...

Nestlé plans to pay $2 billion (€1.7 billion) to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss compa...

The health science arm of Nestlé SA will pay $98 million (€87.1 million) to raise its stake in Aimmune Therapeutics Inc, the drug dev...